Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Sunshine Biopharma, Inc | sbfm_ex991.htm |
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
May 22, 2020
SUNSHINE BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its
charter)
|
Colorado
|
000-52898
|
20-5566275
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer ID No.)
|
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
(Address
of principal executive offices)
514) 426-6161
(Issuer’s
Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item 7.01
Regulation FD Disclosure
Attached
is a copy of a press release being issued by us regarding the
filing of a new patent application more fully described in Item
8.01 below. a copy of which is attached as Exhibit 99.1 and is
hereby incorporated.
Item
8.01
Other
Events
On May
22, 2020, we filed a patent application in the United States for a
new treatment for Coronavirus infections, including COVID-19. Our
patent application covers composition subject matter pertaining to
small molecules for inhibition of the main Coronavirus protease
(Mpro), an enzyme that is essential for viral replication. The
small molecules covered by the patent application were computer
modelled and designed by Dr. Steve N. Slilaty, our CEO. The patent
application has a priority date of May 22, 2020.
Item
9.01.
Financial
Statements and Exhibits.
(c)
Exhibits.
|
Number
|
|
Exhibit
|
|
|
Press
Release Announcing the filing of the new patent
application described in Item 8.01, above.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
SUNSHINE BIOPHARMA, INC. (Registrant) |
|
|
|
|
|
|
|
|
Date: June 3,
2020
|
By:
|
/s/ Dr. Steve N.
Slilaty
|
|
|
|
|
Dr. Steve N.
Slilaty
|
|
|
|
|
Chief Executive
Officer
|
|